PMID- 34510960
OWN - NLM
STAT- MEDLINE
DCOM- 20210914
LR  - 20210917
IS  - 1473-2300 (Electronic)
IS  - 0300-0605 (Print)
IS  - 0300-0605 (Linking)
VI  - 49
IP  - 9
DP  - 2021 Sep
TI  - Comparisons of the therapeutic safety of seven oral antimuscarinic drugs in 
      patients with overactive bladder: a network meta-analysis.
PG  - 3000605211042994
LID - 10.1177/03000605211042994 [doi]
LID - 03000605211042994
AB  - OBJECTIVES: This network meta-analysis aimed to assess the safety profiles of 
      seven commonly used oral antimuscarinic drugs (darifenacin, fesoterodine, 
      imidafenacin, oxybutynin, propiverine, solifenacin, and tolterodine) in patients 
      with overactive bladder (OAB). METHODS: PubMed, Cochrane Library, EMBASE, CNKI, 
      and Wanfang databases were searched for randomized controlled trials (RCTs). 
      Studies comparing one or more antimuscarinic drugs for treating OAB with reported 
      adverse effects (AEs) were eligible. Data were extracted, and a network 
      meta-analysis was performed by two authors independently. RESULTS: Forty-five 
      RCTs and 124,587 patients were included. The results demonstrated that 
      tolterodine had better safety outcomes for 7 out of 12 major AEs, including dry 
      mouth, constipation, urinary retention, dizziness, urinary tract infection, dry 
      eyes, and dry skin. Darifenacin, fesoterodine, imidafenacin, oxybutynin, and 
      solifenacin presented comparable safety profiles. CONCLUSIONS: Tolterodine may be 
      preferable as it showed a reduced association with important AEs. Darifenacin, 
      fesoterodine, imidafenacin, oxybutynin, and solifenacin have similar safety 
      profiles in treating patients with OAB. Taken together, this analysis provides a 
      valuable overview of the therapeutic safety for oral antimuscarinic drugs and is 
      useful for personalized medicine in patients with OAB.Trial registration: This 
      trial was retrospectively registered at INPLASY (https://inplasy.com/) with the 
      registration number 202170095.
FAU - Yang, Nannan
AU  - Yang N
AD  - Department of Urology Surgery, Xinchang People's Hospital, Zhejiang Province, 
      China.
FAU - Wu, Qiaoyan
AU  - Wu Q
AD  - Department of Urology Surgery, Xinchang People's Hospital, Zhejiang Province, 
      China.
FAU - Xu, Faren
AU  - Xu F
AD  - Department of Urology Surgery, Xinchang People's Hospital, Zhejiang Province, 
      China.
FAU - Zhang, Xiaopeng
AU  - Zhang X
AUID- ORCID: 0000-0001-5161-5660
AD  - Department of Urology Surgery, Xinchang People's Hospital, Zhejiang Province, 
      China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PL  - England
TA  - J Int Med Res
JT  - The Journal of international medical research
JID - 0346411
RN  - 0 (Muscarinic Antagonists)
RN  - 0 (Pharmaceutical Preparations)
RN  - 5T619TQR3R (Tolterodine Tartrate)
SB  - IM
MH  - Humans
MH  - Muscarinic Antagonists
MH  - Network Meta-Analysis
MH  - *Pharmaceutical Preparations
MH  - Tolterodine Tartrate
MH  - *Urinary Bladder, Overactive/drug therapy
PMC - PMC8442499
OTO - NOTNLM
OT  - Antimuscarinic drug
OT  - adverse effect
OT  - network meta-analysis
OT  - overactive bladder
OT  - systematic review
OT  - tolterodine
COIS- Declaration of conflicting interest: The authors declare that there is no 
      conflict of interest.
EDAT- 2021/09/14 06:00
MHDA- 2021/09/15 06:00
PMCR- 2021/09/12
CRDT- 2021/09/13 05:34
PHST- 2021/09/13 05:34 [entrez]
PHST- 2021/09/14 06:00 [pubmed]
PHST- 2021/09/15 06:00 [medline]
PHST- 2021/09/12 00:00 [pmc-release]
AID - 10.1177_03000605211042994 [pii]
AID - 10.1177/03000605211042994 [doi]
PST - ppublish
SO  - J Int Med Res. 2021 Sep;49(9):3000605211042994. doi: 10.1177/03000605211042994.